Cardium Therapeutics presented its financial results for the first quarter ended March 31, and reported on highlights and other recent developments. Academy Medical has a growing customer base of over 35 Veterans Administration and military hospitals within the U.S. -Presentation at the 2013 Phacilitate Annual Cell and Gene Therapy Forum in Washing
This quarterly report on Form 10- Q and other reports filed by the Company from time to time with the Securities and Exchange Commission contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the Company's management as well as estimates and assumptions made by Compa
By a News Reporter-Staff News Editor at OBGYN& Reproduction Week At the 61st Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists in New Orleans, Clearblue unveiled the newest addition to their family of products that will change women's home pregnancy test experiences forever. Cleared by the Food and Drug Administr
Twenty-five years after pharmaceutical giant Eli Lilly unleashed Prozac on the red-braced 80 s, SSRIs are still the world's most popular antidepressants. They are swallowed by more than 40 million people, from Beijing to Beirut, knitting a web of happiness from New York to New Caledonia. Like the Soma of Aldous Huxley's Brave New World, Prozac was
By a News Reporter-Staff News Editor at Marketing Weekly News Valeant Consumer Products, a division of Valeant Pharmaceuticals North America LLC, multinational and specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products, has recognized the size and growth of the U.S. Caladryl is a familiar
May 17 NEW BRITAIN Residents with unwanted or expired prescription and non-prescription drugs are invited to drop them off at the senior center on May 17. New Britain Youth& Family Services/Community Services Department, along with the health department, the police department, the senior center and the Substance Abuse Action Council of Central
By a News Reporter-Staff News Editor at Health& Medicine Week Mylan Inc. announced that it has appointed Deborah M. Autor as senior vice president, Strategic Global Quality and Regulatory Policy. Autor joins Mylan from the U.S. Food and Drug Administration, where she served for 11 years, most recently as deputy commissioner for Global Regulatory
May 17 MEYERSDALE After three drug arrests in connection with two Meyersdale- area methamphetamine labs, Somerset County authorities said they hope a strong message is being sent to drug manufacturers and dealers operating in the region. State police, in conjunction with the Somerset Single County Authority for Drug and Alcohol and Somerset Cou
All comments should be identified with the OMB control number 0910-0537. Also include the FDA docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville, MD 20850, 301-796-7726,...
May 16 NEW BRITAIN Residents with unwanted or expired prescription and non-prescription drugs are invited to drop them off at the senior center on May 17. New Britain Youth& Family Services/Community Services Department, along with the health department, the police department, the senior center and the Substance Abuse Action Council of Central
By a News Reporter-Staff News Editor at Women's Health Weekly Teva Women's Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration has approved the emergency contraceptive Plan B One-Step tablet 1.5 mg for over-the-counter sale to consumers 15 years of age and older in
Helsinn Healthcare SA and Vifor Pharma, announced that the companies have entered into an exclusive license and distribution agreement for netupitant-palonosetron fixed dose combination, a Helsinn product currently in the development stage for the treatment of chemotherapy-induced nausea and vomiting. Under the agreement, Vifor Pharma will have...
It is manufactured by McNeil Consumer Healthcare, which is now a subsidiary of Johnson& Johnson. The FDA has issued warnings that the acetaminophen class of drugs may cause liver damage in some cases and the agency has even taken steps to limit the dosage of these drugs. In January 2011, the FDA limited acetaminophen products to 325 milligrams per
Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results. As used in this quarterly report, the terms "we", "us", "our", the "Company" and "ALRT" mean ALR Technologies Inc, unless otherwise indicated. ALR T
This Quarterly Report on Form 10- Q contains certain "forward-looking statements" within the meaning of Section 27 A of the Securities Act of 1933, as amended, and Section 21 E of the Securities Exchange Act of 1934, as amended, as well as information relating to Aoxing Pharmaceutical Company, Inc. that is based on management's exercise of business
Bio-Path Holdings, Inc. is a development stage company with its lead cancer drug candidate, Liposomal Grb-2, currently in clinical trials. Bio-Path also plans to investigate developing liposome tumor targeting technology, which has the potential to be developed to augment the Company's current delivery technology to improve further the effectivenes
Cardium Therapeutics today presented its financial results for the first quarter ended March 31, 2013, and reported on highlights and other recent developments including:. Including Academy Medical, there are currently over 60 sales representatives selling Excellagen. Excellagen awarded the American Podiatric Medical Association' s Seal of Approval
You should read the following discussion of our financial condition and results of operations in conjunction with our financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10- Q and the description of our business appearing in our Annual Report on Form 10- K for the year ended December 31, 2012, filed with the
The Pain Medication OTC Manufacturing industry manufactures pharmaceutical products that focus on pain relief and are available without a doctor's permission. According to IBISWorld industry analyst Craig Shulman, global pharmaceutical manufacturing has shifted production towards Asia, where labour is cheaper and the plants are larger, leading t
Forward-looking statements may also be made in the Company's other reports filed with or furnished to the SEC and in other documents. PuraMed BioScience, Inc. was incorporated in Minnesota on May 9, 2006, as a wholly-owned subsidiary of Wind Energy America, Inc. for the purpose of engaging in the business of developing and marketing non-prescrip
BestCo announced that it is the new name for BestSweet, a manufacturer, developer and marketer of consumer healthcare products for retailers and marketers of over-the-counter drug products and dietary supplements. According to a release, BestCo has evolved to become a supplier of cough drops, throat drops, soft chews, coated chews and other...
May 14 The Associated Press reported last week the Food and Drug Administration is advising pregnant women and women of child-bearing age to beware of medications that treat migraine headaches. The FDA said those medications, which includes Depakote and Depcaon, should not be taken by pregnant women because of the possible risk of birth defects a
Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC. We, through our wholly owned subsidiary Skinvisible Pharmaceuticals Inc., are a pharmaceutical research and development company that has developed and patented an...
You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included in our Annual Report on Form 10- K, as well as the information relating to such audited financial statements contained under the heading "Management's Discussion and Analysis of
Actavis, Inc. today announced that the U.S. Food and Drug Administration has accepted for filing Actavis' New Drug Application for a progestin-only transdermal contraceptive patch for use by women to prevent pregnancy. Actavis' progestin-only patch is designed to provide continuous delivery of norethindrone to the systemic circulation during a...
